Cipher Pharmaceuticals Inc is a company that firmly believes in values such as integrity, innovation, and excellence. With a strong corporate philosophy, Cipher strives to provide healthcare solutions that cater to the diverse needs of patients worldwide. By consistently adopting cutting-edge technologies and research, Cipher is committed to delivering high-quality products that improve patients' quality of life. With a customer-centric approach, the company focuses on building strong relationships with healthcare professionals and stakeholders to ensure the best outcomes. Cipher Pharmaceuticals Inc's dedication to ethical practices and continuous improvement makes it a trusted player in the pharmaceutical industry.

Cipher Pharmaceuticals Inc is primarily present in several countries and regions around the world. Some of the key markets where the company operates include Canada and the United States. The company has a significant presence and a strong focus on the North American pharmaceutical market. With its headquarters in Mississauga, Ontario, Cipher Pharmaceuticals Inc also has a presence in various countries globally, including Europe, Latin America, and other international markets. The company's global reach allows it to cater to a diverse range of patients and healthcare professionals, ensuring widespread access to its innovative pharmaceutical products.

Cipher Pharmaceuticals Inc has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Innocutis Holdings LLC in 2014, expanding its product portfolio and market reach. In addition, Cipher successfully secured partnerships and licensing agreements for its pharmaceutical products, strengthening its global presence. The company's focused approach and commitment to research and development have also led to the successful launch of innovative products in various therapeutic areas. Furthermore, Cipher Pharmaceuticals Inc has consistently demonstrated strong financial performance, achieving steady revenue growth and profitability over the years. These achievements highlight the company's dedication towards delivering high-quality pharmaceutical solutions to improve patient outcomes.

Cipher Pharmaceuticals Inc. is a renowned Canadian pharmaceutical company with a rich history and established background. Founded in 2000, Cipher focuses on the development and commercialization of innovative prescription products. With a diverse portfolio ranging from dermatology to cardiometabolic disorders, Cipher has gained a strong foothold in the global pharmaceutical market. The company's strategic partnerships and collaborations have propelled its growth and allowed it to bring new treatments to market. Known for its commitment to excellence, Cipher Pharmaceuticals Inc. continues to make significant contributions to the healthcare industry, delivering high-quality products and improving patients' lives worldwide.

Cipher Pharmaceuticals Inc faces competition from several key players in the market. Some of the main competitors include [competitor 1], [competitor 2], and [competitor 3]. These companies operate in the same industry as Cipher Pharmaceuticals Inc and offer similar products and services. While Cipher Pharmaceuticals Inc has established a strong presence in the market with their innovative solutions, they must continuously strive to stay ahead of the competition and adapt to changing market dynamics.

Cipher Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Cipher Pharmaceuticals Inc. operates as a pharmaceutical company. Their business model focuses on developing, acquiring, and commercializing novel prescription products for targeted therapeutic areas. With a focus on dermatology, they aim to provide innovative solutions to patients and healthcare professionals. Cipher Pharmaceuticals Inc. leverages its expertise in drug formulation and product commercialization to bring high-quality, differentiated treatments to market. Their commitment to research and development, along with strategic partnerships, positions them as a trusted provider of specialized pharmaceutical products.

Cipher Pharmaceuticals KGV ir 21,23.

Cipher Pharmaceuticals KUV ir 13,38.

AlleAktien kvalitātes vērtējums Cipher Pharmaceuticals ir 3/10.

gaidāmā Cipher Pharmaceuticals apgrozījums ir 22,29 milj. USD.

gaidāmā Cipher Pharmaceuticals peļņa ir 14,04 milj. USD.

Cipher Pharmaceuticals Inc is a Canadian company specializing in the development, manufacturing, and marketing of pharmaceutical preparations. The company places great emphasis on research and development to create innovative solutions for patients worldwide. Cipher invests in a variety of therapeutic areas, including dermatology, pain medications, urinary tract diseases, and cardiology. There are products developed for acne, eczema, psoriasis, nail fungus, herpes, and more. Cipher Pharmaceuticals has three main business areas in which it operates: 1. Proprietary Products This business segment focuses on the development and marketing of patented drugs for patients worldwide. The company is strong in dermatology and offers innovative products for skin diseases such as acne, eczema, and psoriasis. An example of a patented product from Cipher is the medical gel Absorica for acne. The patented technology ensures controlled release of isotretinoin, an active ingredient known for its effectiveness in severe acne. 2. In-Licensing and Acquisitions Cipher Pharmaceuticals is also active in the in-licensing and acquisition market. The company acquires the rights to drugs from other companies that are either on the market or still in the development phase. Through this business segment, Cipher gains access to new technologies and drug products that can complement the company's product portfolio. Cipher also seeks partnerships and joint ventures to further grow and expand. 3. Licensing Cipher Pharmaceuticals also offers licenses for its technologies and products on the global market. Cipher has partnerships in European countries, Canada, and the United States. Cipher continuously invests in research and development to create innovative drugs for patients. The company aims to reformulate active ingredients such as isotretinoin to improve their effectiveness while reducing side effects. Overall, Cipher Pharmaceuticals is an innovative, research-based company. The development of patented medications as well as in-licensing and acquisitions enable the company to expand its product portfolio and fulfill its vision of supporting patients.

Cipher Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Cipher Pharmaceuticals vai uzņēmums nedod dividendes.

Cipher Pharmaceuticals ISIN ir CA17253X1050.

Cipher Pharmaceuticals WKN ir A0B85L.

Cipher Pharmaceuticals simbols ir CPH.TO.

Pēdējo 12 mēnešu laikā Cipher Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Cipher Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Cipher Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Cipher Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Cipher Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Cipher Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Cipher Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 22.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.08.2024..

Pēdējās dividendes izmaksa notika 22.08.2024..

Gadā 2023, Cipher Pharmaceuticals izmaksāja 0 USD dividendes.

Cipher Pharmaceuticals dividendes tiek izmaksātas USD.